Trials that use: Intention-to-treat analysis
New to this method? Read the tutorial →
7,779 results
- Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia: Complete Statistical AnalysisIndependent statistical analysis of Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04652479).
- Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02698891).
- AVR_HEORIndependent statistical analysis of EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05263037).
- AWARD-2Independent statistical analysis of A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01075282).
- AWARD-CHN3Independent statistical analysis of A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- AWARD-JPNIndependent statistical analysis of A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- AWARD-PEDSIndependent statistical analysis of A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- AwareIndependent statistical analysis of HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania: Complete Statistical AnalysisIndependent statistical analysis of Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01654523).
- AXEBEAMIndependent statistical analysis of Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- AXELIndependent statistical analysis of An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00920816).
- Azacitidine and CAPOX in Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and CAPOX in Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01193517).
- Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Azacitidine and Pembrolizumab in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Pembrolizumab in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264404).
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: primary endpoint…
- AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02513563).
- AZI001Independent statistical analysis of Azithromycin in Bronchiolitis Obliterans Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01009619).
- AZMATICS: AZithroMycin/Asthma Trial In Community Settings: Complete Statistical AnalysisIndependent statistical analysis of AZMATICS: AZithroMycin/Asthma Trial In Community Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00266851).
- B-cell Immunity to Influenza (SLVP017)- Year 5, 2013: Complete Statistical AnalysisIndependent statistical analysis of B-cell Immunity to Influenza (SLVP017)- Year 5, 2013: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03020537).
- BAIndependent statistical analysis of Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections: Complete Statistical AnalysisIndependent statistical analysis of Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04884308).
- Baclofen as a Perioperative Analgesic Adjuvant: Complete Statistical AnalysisIndependent statistical analysis of Baclofen as a Perioperative Analgesic Adjuvant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03720717).
- BACOPIndependent statistical analysis of Basel Discharge Communication Project: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01540266).
- Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics: Complete Statistical AnalysisIndependent statistical analysis of Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02223338).
- BAILAIndependent statistical analysis of BAILA: Being Active, Increasing Latinos Healthy Aging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01988233).
- BalanceIndependent statistical analysis of Impaired Regulation of Energy Balance in Elderly People (Balance Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00561145).
- Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04914364).
- Balance Recovery Training for Fall Prevention in Retirement Communities: Complete Statistical AnalysisIndependent statistical analysis of Balance Recovery Training for Fall Prevention in Retirement Communities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02551666).
- Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit: Complete Statistical AnalysisIndependent statistical analysis of Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BALATONIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion: primary endpoint results, effect estimate with confidence…
- BALLAD+Independent statistical analysis of A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid: primary endpoint results, effect estimate with…
- Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy: Complete Statistical AnalysisIndependent statistical analysis of Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04658784).
- Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension – CATALYST: Complete Statistical AnalysisIndependent statistical analysis of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BARIIndependent statistical analysis of Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus: Complete Statistical AnalysisIndependent statistical analysis of Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05188521).
- Barre Exercise in Parkinson’s: Complete Statistical AnalysisIndependent statistical analysis of Barre Exercise in Parkinson's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06203990).
- Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00410059).
- BAY 0 9867 Cipro Pediatric Use Study (QUIP): Complete Statistical AnalysisIndependent statistical analysis of BAY 0 9867 Cipro Pediatric Use Study (QUIP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00761462).
- BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326495).
- BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BBTIndependent statistical analysis of Beneficial Bacteria Treatment for Autism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02504554).
- BCAAIndependent statistical analysis of Mechanisms to Reduce Mental and Physical Fatigue Following Exercise Training in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BCC-RAD-13Independent statistical analysis of Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BDJIndependent statistical analysis of Modulation Effects of Baduanjin Exercise on Subjective Cognitive Decline: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04009382).
- BE ACTIVE 2Independent statistical analysis of A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…